Auto Shanghai 2023 ushers in a new era of intelligent vehicles! Nearly 20 mass-produced models equipped with RoboSense LiDAR
28.4.2023 12:28:00 EEST | Business Wire | Press release
RoboSense, a world-leading provider of Smart LiDAR Sensor Systems, announced today its M series LiDAR products, which assisted more than 10 well-known global automakers showcase nearly 20 intelligent vehicle models at the 20th Shanghai International Automobile Industry Exhibition 2023 (referred to as the Auto Shanghai 2023), presenting the excellent performance of their intelligent driving assistance systems to the audience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230428005133/en/
Part of EV models equipped with RoboSense LiDAR showcased at Auto Shanghai 2023 (Photo: Business Wire)
This year's Shanghai Auto Show brought more than 1,000 exhibitors, including well-known global car companies, independent domestic car brands, new car-making forces, and automobile technology companies, using 13 indoor exhibition halls.
The M series sensors were the first LiDAR in the world to achieve automotive-grade mass production. It uses a patented revolutionary chip-based 2D scanning solution that boasts supreme performance and reliability.
According to the statistics obtained by industry media, “there are 38 models equipped with LiDARs at Auto Shanghai 2023, of which RoboSense is the biggest winner, being the LiDAR supplier of 18 of them”，the brands including SAIC IM, BYD, XPeng, FAW Hongqi, GWM WEY, Chery Exeed, Geely, GAC Hyper, Lotus, etc. To date, RoboSense has earned design wins for mass production of LiDAR products for over 50 vehicle models with 18 automakers.
As the theme of this auto show, "Embracing the New Era of the Automobile Industry," the global automobile industry is accelerating its transformation and upgrading towards electrification and intelligence. Against this backdrop, this year's Shanghai Auto Show is not only a concentrated display of product strength for the global automobile industry's intelligent transformation and upgrading, but also strong evidence of RoboSense's efforts to accelerate the intelligent development of the automobile industry.
RoboSense has invested heavily in building world-class product development and testing capabilities, while expanding its global footprint with operational headquarters in both Europe and the US. Its capabilities include intelligent manufacturing system in Southern China, along with the world’s first and only certified accreditation automotive-grade LiDAR laboratory, its China National Accreditation Service (CNAS) certified LiDAR lab, with more than 200 advanced pieces of testing equipment.
RoboSense's M series LiDAR technology has played a significant role in the intelligent transformation of the automobile industry, and the 2023 Shanghai Auto Show has demonstrated the excellent performance of intelligent driving assistance systems, showcasing the industry's progress towards electrification and intelligence.
About RoboSense (www.robosense.ai):
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. Comprising LiDAR sensors, AI algorithms and IC chipsets, its portfolio transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230428005133/en/
Contact information
Grace Ye
media@robosense.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom